Aiji Taikang completed 50 million yuan B round of financing, Jinke Jun venture capital lead investment

Aji Taikang Biotech (Beijing) Co., Ltd. announced the completion of 50 million B round of financing, the current round of financing by focusing on technology innovation-driven technology enterprises to invest in Jinke Jun venture capital investment, Lenovo Star and other old shareholders continue to follow the completion of the investment.It is understood that this round of funds will be mainly used to promote the rapid productization of technology platform, accelerate the domestic market sales layout and business depth expansion.Founded in 2014, Aiji Taikang is a high-tech enterprise located in Zhongguancun Life Sciences Park in Beijing. Focusing on research and development innovations in high-volume sequencing target capture technology and the design and production of gene testing products, Aji taikang is a production service platform company driven by gene testing technology. Relying on two core technologies of independent intellectual property rights, TargetSeq® and MultipSeq®, Ajitakang has developed a diversified product system that includes gene capture reagents and kits, capture sequencing solutions, and synthetic biology, and is committed to continuously advancing the transformation and application of targeted capture technologies in precision medicine, scientific research, large health, agriculture, public health and forensics.To date, Ajitakang has provided quality, efficient and cost-intensive kit custom production and genetic testing solutions to hundreds of sequencing companies, thousands of doctors and researchers.Prior to this, Aiji Taikang has also won the favor of Price Hua Capital, Zhongguancun Development Group and other institutions, a total of more than 100 million yuan raised, and as the NGS upstream field rarely "Made in China" brand, enjoy a reputation in the industry. (Arterial mesh)